Skip to main content
39°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intra-Cellular Therapies Inc. - Common Stock
(NQ:
ITCI
)
131.37
+0.12 (+0.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intra-Cellular Therapies Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
March 07, 2025
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
Via
Benzinga
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
February 25, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
February 24, 2025
From
Halper Sadeh LLC
Via
Business Wire
Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday
February 24, 2025
Via
Benzinga
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
February 21, 2025
Via
Benzinga
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
January 22, 2025
Via
Benzinga
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
February 24, 2025
Via
Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
February 18, 2025
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.
Via
Benzinga
Exposures
Product Safety
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders
February 04, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
February 04, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
January 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
January 22, 2025
Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders
January 21, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
January 21, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Top 4 Health Care Stocks You May Want To Dump In Q1
January 21, 2025
Via
Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
January 19, 2025
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.
Via
Benzinga
MarketBeat Week in Review – 01/13 - 01/17
January 18, 2025
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally
Via
MarketBeat
Topics
Economy
Energy
Exposures
Fossil Fuels
Interest Rates
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
January 17, 2025
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive
Via
MarketBeat
Exposures
Product Safety
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders
January 13, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
January 13, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
January 13, 2025
From
Ademi LLP
Via
Business Wire
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
January 13, 2025
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.
Via
Benzinga
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
January 13, 2025
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
January 13, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Nasdaq, S&P 500 Fall As Bond Yields Pressure Tech Stocks
January 13, 2025
Stocks are a mixed bag to start the week.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Exposures
US Equities
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
January 13, 2025
Via
Benzinga
Exposures
Fossil Fuels
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
January 13, 2025
Via
Benzinga
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
January 13, 2025
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.
Via
Benzinga
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
January 13, 2025
The deal values the smaller biotech company at a 39% premium to last week's closing price.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.